Influence of Neostigmine vs. Sugammadex on PORC and PPCs by Ultrasonography

Overview

This trial aims to compare the incidence of postoperative residual curarisation (PORC) and postoperative pulmonary complications (PPCs) in the SUG and NEO group by means of diaphragm ultrasonography and LUS, so as to conclude whether SUG can outperform NEO in preventing occurrence of PORC and PPCs.

Full Title of Study: “Comparison of the Effects of Neostigmine and Sugammadex on Postoperative Residual Curarization and Postoperative Pulmonary Complications Detected by Diaphragm and Lung Ultrasonography: A Study Protocol for Prospective Double-blind Randomized Controlled Trial.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Care Provider)
  • Study Primary Completion Date: July 2022

Detailed Description

The incidence of postoperative residual curarisation (PORC) is about 2%-64% worldwide, which may be an underling risk factor of postoperative pulmonary complications (PPCs), causing many undesirable effects on patients. Thus, reversal drugs of neuromuscular blocking agents (NMBAs) such as neostigmine (NEO) and sugammadex (SUG) have been administrated, and SUG maybe perform better in preventing PORC. Different supplementary methods to help identify PORC or PPCs have also been reported, such as adductor of pollicis acceleromyography and lung ultrasound (LUS). Recently, diaphragm ultrasonography has been used to evaluate PORC, as a novel approach.In this prospective, double-blind, randomized controlled trial, we will enroll 414 patients of American Society of Anesthesiologists physical status I-III, aged over 60 years, who will be scheduled to undergo arthroplasty surgery under general anesthesia. Participants will be randomized into NEO and SUG group receiving neostigmine and sugammadex as reversal drug respectively. The primary outcomes will be the incidence of PPCs in NEO and SUG group respectively. The secondary outcome is the incidence of PORC in the two groups.We hypothesize that: 1) the incidence of PPCs is lower after reversal with SUG than with NEO, 2) using the method of diaphragm ultrasonography, the incidence PORC is lower after reversal with SUG than with NEO, 3) the incidence of PPCs can be predicted by LUS and by evaluating whether there is PORC through diaphragmatic ultrasound.

Interventions

  • Drug: sugammadex as reversal drugs
    • use sugammadex to reverse neuromuscular blockade

Arms, Groups and Cohorts

  • Experimental: SUG group
    • sugammadex as reversal drugs
  • No Intervention: NEO group
    • neostigmine as reversal drugs

Clinical Trial Outcome Measures

Primary Measures

  • incidence of postoperative pulmonary complications
    • Time Frame: 30 days after surgery
    • incidence of postoperative pulmonary complications

Secondary Measures

  • Evaluation of diaphragmatic and pulmonary function by means of diaphragm and lung ultrasonography
    • Time Frame: preoperatively, 10min and 30min after extubation for diaphragm ultrasonography and LUS
    • Evaluation of diaphragmatic and pulmonary function by means of diaphragm and lung ultrasonography(LUS)

Participating in This Clinical Trial

Inclusion Criteria

1. American Society of Anesthesiologists (ASA) physical status I-III 2. Aged over 60 years 3. Anesthesia induction with rocuronium as NMBAs, maintenance with volatile sevoflurane 4. Scheduled to undertake joint surgery 5. Signed the informed consent form Exclusion Criteria:

1. Those with a history of hepatic or renal disease, chronic or acute alcoholism, allergy or hypersensitivity to sugammadex or neostigmine, current medication with effects on the central nervous system, a history of dysfunction of neuromuscular system 2. Those with diaphragm insufficiency or massive pleural effusion 3. Women who are pregnant or nursing 4. Those undergoing upper abdominal laparotomy, after which we cannot obtain a satisfactory ultrasound imaging or do not have space for placement of ultrasonic probe 5. Declined to participate

Gender Eligibility: All

Minimum Age: 60 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Peking Union Medical College Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jie YI, deputy director of surgery department – Peking Union Medical College Hospital
  • Overall Official(s)
    • ZHANG YUGUAN, doctoral, Principal Investigator, Peking Union Medical College Hospital
  • Overall Contact(s)
    • CHEN YING, +8619801103037, ddlondon@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.